Skip to Content

Generic Tepmetko Availability

Tepmetko is a brand name of tepotinib, approved by the FDA in the following formulation(s):

TEPMETKO (tepotinib hydrochloride - tablet;oral)

  • Manufacturer: EMD SERONO INC
    Approval date: February 3, 2021
    Strength(s): EQ 225MG BASE [RLD]

Has a generic version of Tepmetko been approved?

No. There is currently no therapeutically equivalent version of Tepmetko available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tepmetko. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 8,329,692

    Patent expiration dates:

    • October 30, 2029
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 8,580,781

    Patent expiration dates:

    • March 19, 2030
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 8,658,643

    Patent expiration dates:

    • July 4, 2028
      ✓ 
      Patent use: TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
  • Patent 8,921,357

    Patent expiration dates:

    • May 30, 2028
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 8,927,540

    Patent expiration dates:

    • July 21, 2028
      ✓ 
      Patent use: TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, HAVING A MET KINASE ALTERATION(S) BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
  • Patent 9,062,029

    Patent expiration dates:

    • July 4, 2028
      ✓ 
      Drug product
  • Patent 9,284,300

    Patent expiration dates:

    • April 29, 2028
      ✓ 
      Drug product
  • Patent 9,403,799

    Patent expiration dates:

    • July 4, 2028
      ✓ 
      Patent use: TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • February 3, 2026 - NEW CHEMICAL ENTITY
    • February 3, 2028 -

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.